Brainstorm Cell Therapeutics Inc. (BCLI) earnings
BCLI earnings moved a median of +0.22% by the close. Quarterly and annual BCLI reports and results, each read against the price at its own news timestamp. Back to the BCLI overview →
25 measured BCLI earnings events.
Where these BCLI earnings landedvs 25 measured BCLI earnings reactions
| Middle 50% of BCLI earnings reactions | -4.66% to +10.82% |
|---|---|
| Median reaction (to close) | +0.22% |
| Measured reactions | 25 |
Point-in-time · zero look-ahead
Half of the 25 BCLI earnings events with a measured close landed between -4.66% and +10.82%; 56% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | +0.00% | +9.64% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +9.64% | |
| BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update | Press release | +0.00% | -1.41% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -1.41% | |
| Form 10-K BRAINSTORM CELL THERAPEU For: Dec 31 | SEC filing · Form 10-K | +0.67% | +6.24% | |
| BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | +10.82% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +10.82% | |
| BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | -5.80% | -12.54% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Jun 30 | SEC filing · Form 10-Q | -5.80% | -12.54% | |
| BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.86% | +13.79% | |
| BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 | Press release | -9.52% | -7.94% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Mar 31 | SEC filing · Form 10-Q | +0.86% | +13.79% | |
| BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 | Press release | +0.00% | -2.42% | |
| Form 10-K BRAINSTORM CELL THERAPEU For: Dec 31 | SEC filing · Form 10-K | -2.92% | +5.88% | |
| BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | +3.09% | +14.15% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Sep 30 | SEC filing · Form 10-Q | +3.09% | +14.15% | |
| BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.03% | -4.66% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Jun 30 | SEC filing · Form 10-Q | +0.03% | -4.66% | |
| BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update | Press release | -1.17% | -7.94% | |
| BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +1.94% | -6.92% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Mar 31 | SEC filing · Form 10-Q | +1.94% | -6.92% | |
| Form 10-K BRAINSTORM CELL THERAPEU For: Dec 31 | SEC filing · Form 10-K | +0.08% | +21.59% | |
| BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update | Press release | -0.54% | +0.22% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Sep 30 | SEC filing · Form 10-Q | -0.54% | +0.22% | |
| BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update | Press release | +5.66% | +6.99% |
Keep exploring
More BCLI: analyst actions → · SEC filings → · BCLI overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | 664 | -0.07% | 48% |
| UroGen Pharma Ltd. - Ordinary Shares (URGN) | 664 | +0.13% | 53% |
| OPHTHOTECH CORP COMMON (OPHT) | 660 | -0.20% | 43% |
| Gritstone bio, Inc. (GRTS) | 659 | -0.01% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.